JP2013531679A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531679A5
JP2013531679A5 JP2013518765A JP2013518765A JP2013531679A5 JP 2013531679 A5 JP2013531679 A5 JP 2013531679A5 JP 2013518765 A JP2013518765 A JP 2013518765A JP 2013518765 A JP2013518765 A JP 2013518765A JP 2013531679 A5 JP2013531679 A5 JP 2013531679A5
Authority
JP
Japan
Prior art keywords
antibody
formulation
seq
amino acid
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013518765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531679A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/042838 external-priority patent/WO2012003470A2/en
Publication of JP2013531679A publication Critical patent/JP2013531679A/ja
Publication of JP2013531679A5 publication Critical patent/JP2013531679A5/ja
Pending legal-status Critical Current

Links

JP2013518765A 2010-07-02 2011-07-01 抗体製剤 Pending JP2013531679A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36120910P 2010-07-02 2010-07-02
US61/361,209 2010-07-02
PCT/US2011/042838 WO2012003470A2 (en) 2010-07-02 2011-07-01 Antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015166305A Division JP2016026164A (ja) 2010-07-02 2015-08-26 抗体製剤

Publications (2)

Publication Number Publication Date
JP2013531679A JP2013531679A (ja) 2013-08-08
JP2013531679A5 true JP2013531679A5 (enExample) 2014-08-14

Family

ID=45402685

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013518765A Pending JP2013531679A (ja) 2010-07-02 2011-07-01 抗体製剤
JP2015166305A Pending JP2016026164A (ja) 2010-07-02 2015-08-26 抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015166305A Pending JP2016026164A (ja) 2010-07-02 2015-08-26 抗体製剤

Country Status (9)

Country Link
US (1) US8754195B2 (enExample)
EP (1) EP2588141A4 (enExample)
JP (2) JP2013531679A (enExample)
CN (1) CN103108658B (enExample)
AU (2) AU2011274363A1 (enExample)
BR (1) BR112012033457A2 (enExample)
CA (1) CA2803998A1 (enExample)
SG (1) SG186421A1 (enExample)
WO (1) WO2012003470A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
JP6157611B2 (ja) * 2012-06-21 2017-07-05 ユセベ ファルマ ソシエテ アノニム 医薬製剤
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
BR112016006397B1 (pt) * 2013-09-27 2024-01-16 Genentech, Inc Formulações de anticorpo de anti-pdl1, seu uso, artigo de fabricação e composição
JP6799904B2 (ja) * 2014-07-31 2020-12-16 キユーピー株式会社 含水エタノール製剤及びその製造方法、並びに、リゾチーム加工品及び/又はその塩並びにその製造方法
CA2966905A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
DK3380525T3 (da) * 2015-11-25 2024-01-29 Immunogen Inc Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
WO2017095848A1 (en) 2015-11-30 2017-06-08 Medimmune, Llc Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
AU2016369557B2 (en) 2015-12-16 2022-10-20 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles
CN105920600A (zh) * 2016-04-19 2016-09-07 上海景泽生物技术有限公司 一种稳定的抗vegf抗体制剂及其用途
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
EP4271412A4 (en) * 2020-12-30 2024-12-04 Ammax Bio, Inc Extended local release of antibodies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010013A1 (en) 1989-02-09 1990-09-07 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce TYPE oc PLATELET-DERIVED GROWTH FACTOR RECEPTOR GENE
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
WO1992013867A1 (en) 1991-01-31 1992-08-20 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
IE920318A1 (en) 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
US5444151A (en) 1992-05-15 1995-08-22 Ludwig Institute For Cancer Research Platelet derived growth factor antagonists
DK2275119T3 (da) * 1995-07-27 2013-11-11 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
EP0999853B1 (en) * 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20030165831A1 (en) 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
ATE442862T2 (de) * 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
EP1409018B1 (en) 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
MXPA04007924A (es) * 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
WO2004050850A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2560046A1 (en) 2004-03-16 2005-09-22 Dnavec Research Inc. Methods for suppressing tumor proliferation
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
PL2100618T3 (pl) * 2005-06-17 2014-07-31 Imclone Llc Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości
EP2029163A4 (en) * 2006-06-14 2010-08-11 Imclone Llc LYOPHILIZED FORMULATIONS OF ANTI-EGFR ANTIBODIES
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery

Similar Documents

Publication Publication Date Title
JP2013531679A5 (enExample)
Shang et al. Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies
Mejias et al. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection
JP2020518599A5 (enExample)
JP2013543505A5 (enExample)
JP2024016177A5 (enExample)
JP2013500947A5 (enExample)
JP2020518600A5 (enExample)
RU2012131099A (ru) Препарат антитела
JP2021504372A5 (enExample)
JP2018188437A5 (enExample)
JP2019504086A5 (enExample)
JP2018076350A5 (enExample)
JP2016534052A5 (enExample)
RU2017107847A (ru) Стабильный состав на основе антитела к il-4r-альфа
WO2010100200A3 (en) Lyophilised antibody formulation
RU2011127913A (ru) Составы, содержащие антитела
CN111050791A (zh) 用于抗tim-3抗体的给药方案及其用途
JP2020158505A5 (enExample)
JP2019509311A5 (enExample)
JP2016520075A5 (enExample)
JP2017514868A5 (enExample)
JP2013537212A5 (enExample)
RU2018129077A (ru) Стабильная фармацевтическая композиция
JP2019501920A5 (enExample)